PMID- 35236240
OWN - NLM
STAT- MEDLINE
DCOM- 20220308
LR  - 20220502
IS  - 1525-6049 (Electronic)
IS  - 0886-022X (Print)
IS  - 0886-022X (Linking)
VI  - 44
IP  - 1
DP  - 2022 Dec
TI  - Proton pump inhibitor usage is associated with higher all-cause mortality and CV 
      events in peritoneal dialysis patients.
PG  - 407-414
LID - 10.1080/0886022X.2022.2043903 [doi]
AB  - OBJECTIVES: A long period of inappropriate proton pump inhibitors (PPI) treatment 
      has been proved to be associated with adverse prognosis in general population and 
      hemodialysis patients. This study was conducted to clarify the impact of PPI 
      usage on mortality and adverse cardiovascular (CV) events in peritoneal dialysis 
      (PD) patients. METHODS AND DESIGN: This is a retrospective study. A total of 905 
      patients were enrolled from two PD centers, including 211 patients on PPI 
      treatment and 618 patients not on PPIs. Kaplan-Meier curves were used to identify 
      the incidence of adverse outcomes. Multivariate Cox regression models and inverse 
      probability of treatment weighting (IPTW) were applied to analyze hazard ratios 
      (HRs) for adverse outcomes. RESULTS: During follow-up, 162 deaths and 102 CV 
      events were recorded. Kaplan-Meier curve demonstrated all-cause mortality 
      (log-rank test p = .018) and CV events (log-rank test p = .024) were 
      significantly higher in PPI usage group. Multivariate Cox regression models and 
      IPTW showed that PPI usage was an indicator for all-cause mortality (HR = 1.35, 
      95%CI = 1.09-1.67, p = .006) and CV events (HR = 1.78, 95%CI = 1.35-2.32, 
      p < .001). CONCLUSIONS: PPI usage is associated with higher all-cause mortality 
      and CV events in PD patients. Clinicians are supposed to be more careful when 
      using PPI and need to master the indications more rigorously in patients 
      receiving PD treatment.
FAU - Zeng, Yingsi
AU  - Zeng Y
AD  - Department of Nephrology, The Second Affiliated Hospital, Guangzhou Medical 
      University, Guangzhou, China.
FAU - Liu, Lingling
AU  - Liu L
AD  - Department of General Medicine, The Third Affiliated Hospital, Sun Yat-sen 
      University, Guangzhou, China.
FAU - Zhu, Liya
AU  - Zhu L
AD  - Department of Nephrology, The Second Affiliated Hospital, Guangzhou Medical 
      University, Guangzhou, China.
FAU - Zhan, Xiaojiang
AU  - Zhan X
AD  - Department of Nephrology, The First Affiliated Hospital of Nanchang University, 
      Nanchang, Jiangxi, China.
FAU - Peng, Fenfen
AU  - Peng F
AD  - Department of Nephrology, Zhujiang Hospital, Southern Medical University, 
      Guangzhou, China.
FAU - Feng, Xiaoran
AU  - Feng X
AD  - Department of Nephrology, Jiujiang NO.1 People's Hospital, Jiangxi, China.
FAU - Zhou, Qian
AU  - Zhou Q
AD  - Department of Medical Statistics, Clinical Trials Unit, The First Affiliated 
      Hospital, Sun Yat-sen Univeristy, Guangzhou, China.
FAU - Zhang, Yujing
AU  - Zhang Y
AD  - Department of Nephrology, The Second Affiliated Hospital, Guangzhou Medical 
      University, Guangzhou, China.
FAU - Wang, Zebin
AU  - Wang Z
AD  - Department of Nephrology, The Second Affiliated Hospital, Guangzhou Medical 
      University, Guangzhou, China.
FAU - Liang, Jianbo
AU  - Liang J
AD  - Department of Nephrology, The Second Affiliated Hospital, Guangzhou Medical 
      University, Guangzhou, China.
FAU - Li, Jiao
AU  - Li J
AD  - Department of Nephrology, The Second Affiliated Hospital, Guangzhou Medical 
      University, Guangzhou, China.
AD  - Department of Cardiology, The Second Affiliated Hospital, Guangzhou Medical 
      University, Guangzhou, China.
FAU - Wen, Yueqiang
AU  - Wen Y
AD  - Department of Nephrology, The Second Affiliated Hospital, Guangzhou Medical 
      University, Guangzhou, China.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Ren Fail
JT  - Renal failure
JID - 8701128
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Proton Pump Inhibitors)
SB  - IM
MH  - *Cardiovascular Diseases/diagnosis/drug therapy/epidemiology
MH  - China/epidemiology
MH  - Comorbidity
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Kaplan-Meier Estimate
MH  - *Kidney Failure, Chronic/mortality/therapy
MH  - Male
MH  - Middle Aged
MH  - Platelet Aggregation Inhibitors/adverse effects/therapeutic use
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - *Proton Pump Inhibitors/adverse effects/therapeutic use
MH  - Renal Dialysis/*methods
MH  - Retrospective Studies
MH  - Risk Factors
PMC - PMC8896194
OTO - NOTNLM
OT  - Peritoneal dialysis
OT  - all-cause mortality
OT  - cardiovascular event
OT  - proton pump inhibitors
COIS- No potential conflict of interest was reported by the author(s).
EDAT- 2022/03/04 06:00
MHDA- 2022/03/09 06:00
PMCR- 2022/03/02
CRDT- 2022/03/03 05:30
PHST- 2022/03/03 05:30 [entrez]
PHST- 2022/03/04 06:00 [pubmed]
PHST- 2022/03/09 06:00 [medline]
PHST- 2022/03/02 00:00 [pmc-release]
AID - 2043903 [pii]
AID - 10.1080/0886022X.2022.2043903 [doi]
PST - ppublish
SO  - Ren Fail. 2022 Dec;44(1):407-414. doi: 10.1080/0886022X.2022.2043903.